LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects.
about
Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately respondinFocus on biosimilar etanercept - bioequivalence and interchangeability
P2860
LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
LBEC0101, A Proposed Etanercep ...... duct in Healthy Male Subjects.
@en
type
label
LBEC0101, A Proposed Etanercep ...... duct in Healthy Male Subjects.
@en
prefLabel
LBEC0101, A Proposed Etanercep ...... duct in Healthy Male Subjects.
@en
P2093
P2860
P1433
P1476
LBEC0101, A Proposed Etanercep ...... oduct in Healthy Male Subjects
@en
P2093
Heechan Lee
Howard Lee
Hyewon Chung
In-Jin Jang
Kyung-Sang Yu
Seo Hyun Yoon
SeungHwan Lee
Sung Mo Yang
P2860
P2888
P304
P356
10.1007/S40259-017-0230-9
P50
P577
2017-08-01T00:00:00Z